Novaliq announced that NovaTears, a novel topical treatment of dry eye disease and meibomian gland dysfunction (MGD), is now also available in Australia.
Just 8 months after launching in New Zealand, AFT Pharmaceuticals Ltd (AFT) has achieved registration of NovaTears in Australia. AFT, a New Zealand-based pharmaceutical company listed on ASX and NZX, is an ophthalmic leader in the region and commercializes NovaTears across Australasia.
NovaTears is the first and only water-free topical eye drop treatment specifically developed to treat patients with dry eye disease. According to the latest TFOS DEWS II definition and classification report, patients with tear-lipid dysfunction account for the greater proportion of all dry eye disease patients. With the distribution of NovaTears an adequate treatment option for evaporative dry eye is available in Australia now.
NovaTears has a unique mode of actions: one drop immediately stabilizes the lipid layer without causing vision blurring for several hours. Clinically validated in four clinical trials, NovaTears eye drops have been proven to be safe and efficacious for treating the signs and symptoms of dry eye disease and MGD. A large number of objective disease parameters such as tear film breakup time, corneal and conjunctival fluorescein staining but also a number of expressible meibomian glands and meibum quality have been improved under NovaTears treatment.
“With the introduction of NovaTears, dry eye sufferers in Australia now have a new and highly efficacious treatment option that provides significant improvement to the signs and symptoms of evaporative dry eye disease,” Christian Roesky, PhD, managing director and CEO, Novaliq, said in a company news release. “Unlike other currently available DED products, NovaTears provides more than comfort: it stabilizes the lipid layer several hours and restores the natural tear film of the eye over time. I am confident that patients will welcome this breakthrough.”